ASCO 2017 | Treating indolent and mantle cell lymphoma: results of the BRIGHT 5 year follow up study
Ian Flinn, MD, PhD, from The Center for Blood Cancers, Tennessee Oncology, Nashville, TN, gives an overview of the results from the long term follow up of the BRIGHT study, a randomized Phase III trial which compares bendamustine and rituximab (BR) to R-CHOP or R/-CVP in patients with indolent or mantle cell lymphoma.
Dr Flinn explains that the study (NCT00877006) showed that progression free survival, duration response and event free survival is superior for patients who receive BR versus R-CHOP or R/-CVP combination chemotherapies. There was however no difference in overall survival, backing up initial results from the earlier study that BR is non-inferior to R-CHOP or R/-CVP.
The study saw some differences in adverse events, for example, there was more second malignancies in patients who received bendamustine and rituximab. Furthermore, there was shown to be a difference in toxicity profiles between the two therapies.
Dr Flinn explains that these results are all important information for doctors when it comes to deciding what to use as front line therapy.
Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.
